Literature DB >> 24523396

Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Abby M Bailey1, Daniel P Wermeling.   

Abstract

BACKGROUND: Deaths related to opioid overdose have increased in the past decade. Community-based pharmacy practitioners have worked toward overcoming logistic and cultural barriers to make naloxone distribution for overdose prevention a standard and accepted practice.
OBJECTIVE: To describe outpatient naloxone dispensing practices, including methods by which practitioners implement dispensing programs, prescribing patterns that include targeted patient populations, barriers to successful implementation, and methods for patient education.
METHODS: Interviews were conducted with providers to obtain insight into the practice of dispensing naloxone. Practitioners were based in community pharmacies or clinics in large metropolitan cities across the country.
RESULTS: It was found that 33% of participating pharmacists practice in a community-pharmacy setting, and 67% practice within an outpatient clinic-based location. Dispensing naloxone begins by identifying patient groups that would benefit from access to the antidote. These include licit users of high-dose prescription opioids (50%) or injection drug users and abusers of prescription medications (83%). Patients were identified through prescription records or provider screening tools. Dispensing naloxone required a provider's prescription in 5 of the 6 locations identified. Only 1 pharmacy was able to exercise pharmacist prescriptive authority within their practice.
CONCLUSION: Outpatient administration of intramuscular and intranasal naloxone represents a means of preventing opioid-related deaths. Pharmacists can play a vital role in contacting providers, provision of products, education of patients and providers, and dissemination of information throughout the community. Preventing opioid overdose-related deaths should become a major focus of the pharmacy profession.

Entities:  

Keywords:  antidote; intranasal; naloxone; opioids; overdose

Mesh:

Substances:

Year:  2014        PMID: 24523396      PMCID: PMC4361936          DOI: 10.1177/1060028014523730

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  25 in total

1.  Pharmaceutical overdose deaths, United States, 2010.

Authors:  Christopher M Jones; Karin A Mack; Leonard J Paulozzi
Journal:  JAMA       Date:  2013-02-20       Impact factor: 56.272

2.  Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting.

Authors:  Erik D Barton; Christopher B Colwell; Timothy Wolfe; Dave Fosnocht; Craig Gravitz; Tamara Bryan; Will Dunn; Jeff Benson; Jeff Bailey
Journal:  J Emerg Med       Date:  2005-10       Impact factor: 1.484

3.  Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose.

Authors:  Anne-Maree Kelly; Debra Kerr; Paul Dietze; Ian Patrick; Tony Walker; Zeff Koutsogiannis
Journal:  Med J Aust       Date:  2005-01-03       Impact factor: 7.738

4.  Naloxone use in a tiered-response emergency medical services system.

Authors:  Daniel Belz; Jacob Lieb; Tom Rea; Mickey S Eisenberg
Journal:  Prehosp Emerg Care       Date:  2006 Oct-Dec       Impact factor: 3.077

5.  Intranasal administration of naloxone by paramedics.

Authors:  Erik D Barton; Joseph Ramos; Christopher Colwell; Jeff Benson; Jeff Baily; William Dunn
Journal:  Prehosp Emerg Care       Date:  2002 Jan-Mar       Impact factor: 3.077

6.  Out-of-hospital treatment of opioid overdoses in an urban setting.

Authors:  K A Sporer; J Firestone; S M Isaacs
Journal:  Acad Emerg Med       Date:  1996-07       Impact factor: 3.451

7.  Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006.

Authors:  Margaret Warner; Li Hui Chen; Diane M Makuc
Journal:  NCHS Data Brief       Date:  2009-09

8.  Patterns of abuse among unintentional pharmaceutical overdose fatalities.

Authors:  Aron J Hall; Joseph E Logan; Robin L Toblin; James A Kaplan; James C Kraner; Danae Bixler; Alex E Crosby; Leonard J Paulozzi
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

9.  Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City.

Authors:  Tinka Markham Piper; Sasha Rudenstine; Sharon Stancliff; Susan Sherman; Vijay Nandi; Allan Clear; Sandro Galea
Journal:  Harm Reduct J       Date:  2007-01-25

10.  Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.

Authors:  Alexander Y Walley; Ziming Xuan; H Holly Hackman; Emily Quinn; Maya Doe-Simkins; Amy Sorensen-Alawad; Sarah Ruiz; Al Ozonoff
Journal:  BMJ       Date:  2013-01-30
View more
  24 in total

1.  Bariatric Surgery Patients' Response to a Chronic Pain Rehabilitation Program.

Authors:  Anilga Tabibian; Karen B Grothe; Manpreet S Mundi; Todd A Kellogg; Matthew M Clark; Cynthia O Townsend
Journal:  Obes Surg       Date:  2015-10       Impact factor: 4.129

Review 2.  Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities.

Authors:  Brandon D L Marshall; Traci C Green; Jesse L Yedinak; Scott E Hadland
Journal:  Int J Drug Policy       Date:  2016-02-04

Review 3.  Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.

Authors:  Daniel P Wermeling
Journal:  Ther Adv Drug Saf       Date:  2015-02

4.  Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.

Authors:  Amy Bachyrycz; Shikhar Shrestha; Barry E Bleske; Dale Tinker; Ludmila N Bakhireva
Journal:  Subst Abus       Date:  2016-05-10       Impact factor: 3.716

5.  Supporting Community Pharmacies with Implementation of a Web-Based Medication Management Application.

Authors:  Kea Turner; Chelsea Renfro; Stefanie Ferreri; Kim Roberts; Trista Pfeiffenberger; Christopher M Shea
Journal:  Appl Clin Inform       Date:  2018-05-30       Impact factor: 2.342

6.  Opioid-Related Education Provided by Continuing Education Divisions at US Pharmacy Schools.

Authors:  Mandy L Renfro; Leticia R Moczygemba; Jennifer Baumgartner; Glen Baumgart; Lucas G Hill
Journal:  Am J Pharm Educ       Date:  2020-10       Impact factor: 2.047

7.  Take-home naloxone possession among people who inject drugs in rural West Virginia.

Authors:  Sean T Allen; Rebecca Hamilton White; Allison O'Rourke; Suzanne M Grieb; Michael E Kilkenny; Susan G Sherman
Journal:  Drug Alcohol Depend       Date:  2019-09-21       Impact factor: 4.492

8.  Development and evaluation of a pilot overdose education and naloxone distribution program for hospitalized general medical patients.

Authors:  Andrea Jakubowski; Alexander Pappas; Lee Isaacsohn; Felipe Castillo; Mariya Masyukova; Richard Silvera; Louisa Holaday; Evan Rausch; Sameen Farooq; Keith T Veltri; Chinazo O Cunningham; Marcus A Bachhuber
Journal:  Subst Abus       Date:  2018-11-26       Impact factor: 3.716

9.  Promising roles for pharmacists in addressing the U.S. opioid crisis.

Authors:  Wilson M Compton; Christopher M Jones; Jack B Stein; Eric M Wargo
Journal:  Res Social Adm Pharm       Date:  2017-12-31

10.  Pharmacist perceptions of the New Mexico pharmacist-performed tuberculosis testing program.

Authors:  Stefanie J Logothetis; Matthew E Borrego; Melissa H Roberts; Amy Bachyrycz; Graham S Timmins; Bernadette Jakeman
Journal:  J Am Pharm Assoc (2003)       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.